WO1995035113A1 - UTILISATION D'OXYDE FERRIQUE (Fe2O3) DANS LE TRAITEMENT DE DEFICIENCES IMMUNITAIRES, NOTAMMENT DU SIDA - Google Patents

UTILISATION D'OXYDE FERRIQUE (Fe2O3) DANS LE TRAITEMENT DE DEFICIENCES IMMUNITAIRES, NOTAMMENT DU SIDA Download PDF

Info

Publication number
WO1995035113A1
WO1995035113A1 PCT/DE1995/000758 DE9500758W WO9535113A1 WO 1995035113 A1 WO1995035113 A1 WO 1995035113A1 DE 9500758 W DE9500758 W DE 9500758W WO 9535113 A1 WO9535113 A1 WO 9535113A1
Authority
WO
WIPO (PCT)
Prior art keywords
iii
oxide
iron
hiv
treatment
Prior art date
Application number
PCT/DE1995/000758
Other languages
German (de)
English (en)
Inventor
Thomas Bruns
Original Assignee
Thomas Bruns
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Bruns filed Critical Thomas Bruns
Priority to JP8501466A priority Critical patent/JPH10507157A/ja
Publication of WO1995035113A1 publication Critical patent/WO1995035113A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Definitions

  • the invention relates to the use of iron (III) oxide in the case of immune deficiency, in particular aquired immune deficiency syndrome (AIDS) or against immune deficiency caused by the human immunodeficiency virus (HIV).
  • AIDS aquired immune deficiency syndrome
  • HIV human immunodeficiency virus
  • the object of the invention is to provide a preferably orally administrable, non-toxic medicament with an antiviral effect, which can be safely administered to humans and animals after detection of a cellular immune deficiency and the dosage is not a criterion.
  • this fully tolerable and side effect-free drug should be used as a prophylaxis against most diseases caused by viruses.
  • Serological examinations have pien with iron (III) oxide with the exclusion of any side effects led to the following results:
  • Virus detection HIV-I negative; Antigen detection HIV-I negative; Antibody positive.
  • a rapidly developing product from an iron compound as a result of absorption of orally administered iron (I ⁇ I) oxide, e.g. Hemoglobin leads to the accumulation of the molecular cell structure in the organism without having to fear stressful connections with the stomach acid when taking this basic / active substance. Because of this behavior because of the insolubility of iron (III) oxide towards acids, the administration of this compound does not conflict with the physique.
  • the iron (III) oxide was sterilized by heating in an autoclave (134 ° C., 60 min.) And suspended in culture medium after cooling. Aliquots of this suspension were mixed with phytohemagglutinin-activated lymphocytes from peripheral blood or from umbilical cord blood (final concentration 500,000 cells per ml) and incubated for 24 hours in an incubator at 37 ° C / 6% CO2. The cultures were then infected with the various HIV-1 and HIV-2 isolates shown in Table 1.
  • Positive controls experimentation without iron (III) oxide with activated umbilical cord ymphocytes or PBL, which were infected with the various HIV-1 and HIV-2 isolates.
  • Negative controls experimentation with uninfected cells or their culture supernatants.
  • the cultures were assessed daily in a light microscope (examination for the development of a cytopathic effect (CPE) and by measurement of the retrovirus-specific enzyme reverse transcriptase (RT).
  • CPE cytopathic effect
  • RT retrovirus-specific enzyme reverse transcriptase
  • Table 2 summarizes the light microscopic assessment of the cultures from three experiments carried out in parallel with PBL and one experiment with umbilical cord ymophocytes. They mean: - no visible cytopathic effect + visible cytopathic effect
  • Table 2 Assessment of cell cultures for the formation of syncytia (CPE) on day 4 with activated umbilical cord lymphocytes or on day 6 with activated PBL.
  • CPE syncytia
  • Iron (III) oxide virus isolate concentration ( ⁇ g / ml) K31 D34 LAV-2 D194
  • RT reverse transcriptase
  • the enzyme activity is a rough measure of the amount of virus in the supernatant of the cells, however not identical to the amount of infectious virus particles. It is determined by incorporating radioactive thymidine into the DNA. The results of this experiment are therefore given in cpm / ml culture supernatant per 90 minutes.
  • Table 3 Evaluation of the cell cultures (PBL) on the enzyme activity of the reverse transcriptase (cpm / ml per 90 min.) Eight days after the infection.
  • Iron (III) oxide virus isolate concentration ( ⁇ g / ml) K31 D34 LAV-2 D194
  • Iron (III) oxide in fine-grained form and / or its hydrate is used as the starting material for the production of suitable medicaments.
  • the iron (III) oxide can be prepared as such or in the form of uninvolved, non-toxic, solid or liquid extenders or carriers, which are in solid or liquid form, e.g. capsules, coated tablets, microcapsules, suppositories, suspensions, emulsions can be used.
  • the p.o.-usable preparations such as capsules or coated tablets are to be preferred.
  • the production takes place in a manner known per se.
  • iron (III) oxide to be administered largely depends on the field of application and the type of formulation. Included in the following subsequent examples
  • a preferably stomach-soluble gelatin capsule 400 milligrams of fine-grained iron (III) oxide with a grain size of approximately 5 micrometers, intended for daily therapy by oral application in the case of immunodeficiency or

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'oxyde ferrique (Fe2O3) et/ou de son hydrate dans le traitement de déficiences immunitaires, notamment du syndrome d'immunodéficience acquise (SIDA) ou de la déficience immunitaire induite par le virus d'immunodéficience humaine (VIH). Cette substance de base/ce principe actif antiviral(e) n'a pas d'effet toxique, n'est pas critique en ce que qui concerne le dosage, n'induit pas d'effets secondaires et s'utilise de préférence par administration orale après détermination d'une maladie immunodéficiente chez l'homme ou chez l'animal.
PCT/DE1995/000758 1994-06-20 1995-06-19 UTILISATION D'OXYDE FERRIQUE (Fe2O3) DANS LE TRAITEMENT DE DEFICIENCES IMMUNITAIRES, NOTAMMENT DU SIDA WO1995035113A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP8501466A JPH10507157A (ja) 1994-06-20 1995-06-19 鉄（ｉｉｉ）酸化物の使用方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4421159A DE4421159C1 (de) 1994-06-20 1994-06-20 Verwendung von Eisen(III)-oxid (Fe¶2¶O¶3¶) bei Immunschwäche
DEP4421159.7 1994-06-20

Publications (1)

Publication Number Publication Date
WO1995035113A1 true WO1995035113A1 (fr) 1995-12-28

Family

ID=6520801

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1995/000758 WO1995035113A1 (fr) 1994-06-20 1995-06-19 UTILISATION D'OXYDE FERRIQUE (Fe2O3) DANS LE TRAITEMENT DE DEFICIENCES IMMUNITAIRES, NOTAMMENT DU SIDA

Country Status (3)

Country Link
JP (1) JPH10507157A (fr)
DE (1) DE4421159C1 (fr)
WO (1) WO1995035113A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1627641A1 (fr) * 2004-08-04 2006-02-22 Victor Eluwa Compositions pharmaceutiques comprenant des oxydes de métaux et leurs utilisations
WO2006084782A1 (fr) * 2005-02-09 2006-08-17 Vifor (International) Ag Utilisation de composes complexes de fer (iii)
EP1757299A1 (fr) 2005-08-25 2007-02-28 Vifor (International) Ag Complexes de fer III pour traiter les manques de fer en patients avec la maladie intestinale inflammatoire
EP1790356A1 (fr) * 2005-11-24 2007-05-30 Vifor (International) Ag Préparation contenant des complexes de fer(III) et des composés rédoxs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2527158A1 (de) * 1975-06-18 1976-12-23 Herz Eberhard Arzneimittel zur behandlung von infektionskrankheiten und von nicht nachweisbar durch mikroorganismen ausgeloeste entzuendungen in der human- und veterinaermedizin
JPS59190226A (ja) * 1983-04-11 1984-10-29 Shoji Yamashita 二価三価鉄塩およびその製造方法
WO1993003035A1 (fr) * 1991-08-02 1993-02-18 Meiji Milk Products Co., Ltd. Medicament anti-vih
EP0584558A2 (fr) * 1992-07-28 1994-03-02 Snow Brand Milk Products Co., Ltd. Composition pour supprimer l'infection et la croissance du virus de l'immunodéficience humaine en utilisant une protéine fixant le fer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648329B2 (ja) * 1987-09-18 1997-08-27 エフ・ホフマン−ラ ロシュ アーゲー エイズの予防または治療用医薬組成物
WO1990007322A1 (fr) * 1988-12-19 1990-07-12 David Gordon Diagnostic et traitement d'effets viraux
DE4117782C2 (de) * 1991-05-28 1997-07-17 Diagnostikforschung Inst Nanokristalline magnetische Eisenoxid-Partikel, Verfahren zu ihrer Herstellung sowie diagnostische und/oder therapeutische Mittel

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2527158A1 (de) * 1975-06-18 1976-12-23 Herz Eberhard Arzneimittel zur behandlung von infektionskrankheiten und von nicht nachweisbar durch mikroorganismen ausgeloeste entzuendungen in der human- und veterinaermedizin
JPS59190226A (ja) * 1983-04-11 1984-10-29 Shoji Yamashita 二価三価鉄塩およびその製造方法
WO1993003035A1 (fr) * 1991-08-02 1993-02-18 Meiji Milk Products Co., Ltd. Medicament anti-vih
EP0584558A2 (fr) * 1992-07-28 1994-03-02 Snow Brand Milk Products Co., Ltd. Composition pour supprimer l'infection et la croissance du virus de l'immunodéficience humaine en utilisant une protéine fixant le fer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
C. VELATI ET AL.: "Haematological phenotype as indicatior of progression of the disease in HIV infection", INT. CONF. AIDS, vol. 9, no. 1, 1993, pages 454 *
DATABASE WPI Week 8449, Derwent World Patents Index; AN 84-304171 *
SAGRIPANTI, JOSE LUIS ET AL: "Virus inactivation by copper or iron ions alone and in the presence of peroxide", APPL. ENVIRON. MICROBIOL., 1993, VOL. 59, PAGE(S) 4374-6 *
Y. INOYE: "Inhibition of Human Immunodeficiency Virus proliferation by macrocyclic polyamines and their metal complexes", BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 17, no. 2, February 1994 (1994-02-01), pages 243 - 250 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1627641A1 (fr) * 2004-08-04 2006-02-22 Victor Eluwa Compositions pharmaceutiques comprenant des oxydes de métaux et leurs utilisations
WO2006084782A1 (fr) * 2005-02-09 2006-08-17 Vifor (International) Ag Utilisation de composes complexes de fer (iii)
US8722101B2 (en) 2005-02-09 2014-05-13 Vifor (International) Ag Use of iron(III) complex compounds
EP1757299A1 (fr) 2005-08-25 2007-02-28 Vifor (International) Ag Complexes de fer III pour traiter les manques de fer en patients avec la maladie intestinale inflammatoire
EP1790356A1 (fr) * 2005-11-24 2007-05-30 Vifor (International) Ag Préparation contenant des complexes de fer(III) et des composés rédoxs
WO2007060038A2 (fr) * 2005-11-24 2007-05-31 Vifor (International) Ag Preparation comprenant des composes complexes de fer (iii) et une ou plusieurs substances a activite redox
WO2007060038A3 (fr) * 2005-11-24 2008-05-08 Vifor Int Ag Preparation comprenant des composes complexes de fer (iii) et une ou plusieurs substances a activite redox

Also Published As

Publication number Publication date
JPH10507157A (ja) 1998-07-14
DE4421159C1 (de) 1995-08-24

Similar Documents

Publication Publication Date Title
DE2554428C2 (fr)
Sullivan et al. Inhibition of lymphocyte stimulation by measles virus
AT402790B (de) Zusammensetzung und verfahren zur prävention und behandlung von entzündungen mit immunglobulin a
WO1995035113A1 (fr) UTILISATION D'OXYDE FERRIQUE (Fe2O3) DANS LE TRAITEMENT DE DEFICIENCES IMMUNITAIRES, NOTAMMENT DU SIDA
DK166715B1 (da) Farmaceutiske produkt og anvendelse af dette til fremstilling af et kombinationspraeparat til behandling af virusinfektioner
US6630179B1 (en) Oxihumic acid and its use in the treatment of various conditions
Dalakas et al. Treatment of human immunodeficiency virus—related polyneuropathy with 3′‐azido‐2′, 3′‐dideoxythymidine
OA10436A (en) New applications of lysozyme dimer
EP2117567A1 (fr) Bactéries gram positif probiotiques utilisées pour prévenir, atténuer ou supprimer des réactions allergiques chez l'homme
DE102005037096A1 (de) Neues Arzneimittel gegen AIDS und HIV-Vieren
Joncas et al. Interferon in serum and cerebrospinal fluid in subacute sclerosing panencephalitis.
Ackerman et al. Hypersensitivity reactions to drugs in acquired immunodeficiency syndrome
DE2215728A1 (de) Arzneimittel zur behandlung von herpes simplex
Swartzwelder et al. Treatment of ascariasis in children with a single dose of piperazine citrate
EP0429868A2 (fr) Utilisation d'un dérivé de benzodiazepine et de phénylpyrrylkéton dans l'infection rétroviral
DE60118175T2 (de) Methode zur herstellung einer immunotropischen antiviralen zusammensetzung
US11839636B1 (en) Pharmaceutical composition based on plant raw materials: #2.1
US11883418B2 (en) Compound TSYI-ZAC for inhibiting dengue virus infection and medicinal use thereof
DE3825397C2 (de) Verwendung von Papaverin und seinen Salzen zur Bekämpfung von AIDS
DE3913040A1 (de) Pharmazeutische zubereitung und ihre verwendung
DE3925109A1 (de) Extrakte der pflanze acanthospermum hispidum
US7384637B2 (en) Drug for AIDS treatment
RU2038085C1 (ru) Вещество "силлард", обладающее адаптогенной активностью
CN1051451C (zh) 抗aids病毒的药物组合物
CN114903915A (zh) 二氧化铈纳米材料在抑制冠状病毒中的应用

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995922404

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995922404

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 765242

Date of ref document: 19970407

Kind code of ref document: A

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase